Insulin glulisine, marketed as Apidra, received U.S. Food and Drug Administration (FDA) approval in 2004. It is a rapid-acting insulin analog used to improve glycemic control in adults and children with diabetes mellitus [1].
When is Apidra's Patent Protection Expected to End?
Patent exclusivity for Apidra has largely expired, allowing for the development of generic alternatives. Information regarding specific patent expiry dates and remaining exclusivity periods can be found on DrugPatentWatch.com [2].
What are the Differences Between Insulin Glulisine and Other Insulins?
Insulin glulisine is a rapid-acting insulin, meaning it begins to work quickly after injection, typically within 15 minutes. This is in contrast to short-acting, intermediate-acting, and long-acting insulins, which have different onset, peak, and duration of action profiles [3]. Rapid-acting insulins are designed to be taken before meals to help manage post-prandial (after-meal) blood glucose levels.
Are There Generic Versions of Apidra Available?
With patent expiries, generic versions of insulin glulisine have become available. These biosimilar products offer alternative treatment options for patients with diabetes.
How Does Insulin Glulisine Work?
Insulin glulisine is a synthetic insulin analog that mimics the action of human insulin. It binds to insulin receptors on muscle and fat cells, facilitating the uptake of glucose from the bloodstream and reducing glucose production by the liver. This action helps to lower blood glucose levels [3].
What are the Potential Side Effects of Insulin Glulisine?
Common side effects associated with insulin glulisine include hypoglycemia (low blood sugar), which can manifest as dizziness, sweating, confusion, and rapid heartbeat. Other potential side effects may include injection site reactions, lipodystrophy (changes in fat tissue), and allergic reactions [3].
What are the FDA's Requirements for Insulin Approval?
The FDA's approval process for insulins involves rigorous evaluation of safety and efficacy. This includes clinical trials to demonstrate that the drug effectively lowers blood glucose levels and is safe for patient use. For biosimilars, the FDA requires evidence that the product is highly similar to the reference product and has no clinically meaningful differences in safety, purity, and potency [4].
Who Manufactures Insulin Glulisine?
Insulin glulisine (Apidra) was originally developed and manufactured by Sanofi-Aventis. Generic versions may be produced by other pharmaceutical companies [1].
Sources:
1. FDA. (n.d.). Apidra. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021345s000lbl.pdf
2. DrugPatentWatch.com. (n.d.). Insulin Glulisine Patents. Retrieved from https://drugpatentwatch.com/
3. National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Insulin Basics. Retrieved from https://www.niddk.nih.gov/health-information/diabetes/types/insulin-therapy
4. FDA. (n.d.). Biosimilars. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilars-overview